Quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: the global DISCOVER study

被引：0
|
作者：
Nicolucci, A. [1 ]
Gomes, M. B. [2 ]
Khunti, K. [3 ]
Kosiborod, M. [4 ]
Pocock, S. [5 ]
Rathmann, W. [6 ]
Shestakova, M. V. [7 ]
Shimomura, I. [8 ]
Watada, H. [9 ]
Chen, H. [10 ]
Cid-Ruzafa, J. [11 ]
Fenici, P. [12 ]
Hammar, N. [13 ]
Tang, F. [4 ]
Ji, L. [14 ]
机构：
[1] Ctr Outcomes Res & Clin Epidemiol, Pescara, Italy
[2] Univ Estado Rio De Janeiro, Rio De Janeiro, Brazil
[3] Univ Leicester, Leicester, Leics, England
[4] St Lukes Mid Amer Heart Inst, Kansas City, MO USA
[5] London Sch Hyg & Trop Med, London, England
[6] German Diabet Ctr, Dusseldorf, Germany
[7] Diabet Inst, Endocrinol Res Ctr, Moscow, Russia
[8] Osaka Univ, Osaka, Japan
[9] Juntendo Univ, Tokyo, Japan
[10] AstraZeneca, Gaithersburg, MD USA
[11] Evidera, Barcelona, Spain
[12] AstraZeneca, Cambridge, England
[13] AstraZeneca Gothenburg, Molndal, Sweden
[14] Peking Univ, Peoples Hosp, Beijing, Peoples R China
来源：
DIABETOLOGIA | 2018年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
344
引用
收藏
页码：S173 / S174
页数：2
相关论文
共 50 条
  • [31] Comparison of Glucose-Lowering Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis
    Gu, Shuyan
    Hu, Xiaoqian
    Zhen, Xuemei
    Shi, Lizheng
    Shao, Hui
    Sun, Xueshan
    Gu, Yuxuan
    Huang, Minzhuo
    Dong, Hengjin
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (18)
  • [32] Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme
    Nicolucci, Antonio
    Charbonnel, Bernard
    Gomes, Marilia B.
    Khunti, Kamlesh
    Kosiborod, Mikhail
    Shestakova, Marina V.
    Shimomura, Iichiro
    Watada, Hirotaka
    Chen, Hungta
    Cid-Razufa, Javier
    Fenici, Peter
    Hammar, Niklas
    Surmont, Filip
    Tang, Fengming
    Pocock, Stuart
    DIABETES OBESITY & METABOLISM, 2019, 21 (11): : 2474 - 2485
  • [33] Baseline Characteristics of Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: Findings from the J-DISCOVER Study
    Naoto Katakami
    Tomoya Mita
    Mitsuyoshi Takahara
    Toshitaka Yajima
    Fumitaka Wada
    Masaru Kawashima
    Iichiro Shimomura
    Hirotaka Watada
    Diabetes Therapy, 2020, 11 : 1563 - 1578
  • [34] Baseline Characteristics of Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: Findings from the J-DISCOVER Study
    Katakami, Naoto
    Mita, Tomoya
    Takahara, Mitsuyoshi
    Yajima, Toshitaka
    Wada, Fumitaka
    Kawashima, Masaru
    Shimomura, Iichiro
    Watada, Hirotaka
    DIABETES THERAPY, 2020, 11 (07) : 1563 - 1578
  • [35] Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes
    Yang, Jeff Y.
    Moon, Andrew M.
    Kim, Hannah
    Pate, Virginia
    Barritt, A. Sidney
    Crowley, Matthew J.
    Buse, John B.
    Sturmer, Til
    Alexopoulos, Anastasia-Stefania
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2020, 34 (11)
  • [36] What Next after Metformin? A Retrospective Evaluation of the Outcome of Second-Line, Glucose-Lowering Therapies in People with Type 2 Diabetes
    Morgan, Christopher Ll
    Poole, Chris D.
    Evans, Marc
    Barnett, Anthony H.
    Jenkins-Jones, Sara
    Currie, Craig J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (12): : 4605 - 4612
  • [37] Vascular Events in Patients with Type 2 Diabetes in the Year following Initiation of Second-Line Therapy-The DISCOVER Study
    Kosiborod, Mikhail
    Chen, Hungta
    Cid-Ruzafa, Javier
    Fenici, Peter
    Gomes, Marilia B.
    Khunti, Kamlesh
    Pocock, Stuart
    Rathmann, Wolfgang
    Shestakova, Marina V.
    Shimomura, Iichiro
    Surmont, Filip
    Tang, Fengming
    Watada, Hirotaka
    Ji, Linong
    Hammar, Niklas
    DIABETES, 2018, 67
  • [38] Personalizing Glucose-Lowering Therapy in Patients with Type 2 Diabetes and Cardiovascular Disease
    Inzucchi, Silvio E.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2018, 47 (01) : 137 - +
  • [39] Second-line Therapy for Type 2 Diabetes
    Krome, Susanne
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2024, 149 (19) : 1127 - 1128
  • [40] Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study
    Pallares-Carratala, Vicente
    Ruiz-Garcia, Antonio
    Serrano-Cumplido, Adalberto
    Fragoso, Antonio Segura
    Fernandez-Pascual, Veronica
    Sanchez-Sanchez, Beatriz
    Cervera-Perez, Maria Inmaculada
    Alonso-Moreno, Francisco Javier
    Arranz-Martinez, Ezequiel
    Barquilla-Garcia, Alfonso
    Rey-Aldana, Daniel
    Garcia, Jose Polo
    Cinza-Sanjurjo, Sergio
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2025, 37 (01):
12345